Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, double blinded, multi-center phase 2 study to estimate the efficacy and evaluate the safety and tolerability of sorafenib [Nexavar] in combination with AMG 386 or placebo in subjects with metastatic clear cell carcinoma of the kidney

Next Previous
X
Search
Trial Profile

A randomized, double blinded, multi-center phase 2 study to estimate the efficacy and evaluate the safety and tolerability of sorafenib [Nexavar] in combination with AMG 386 or placebo in subjects with metastatic clear cell carcinoma of the kidney

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 17 Dec 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Trebananib (Primary) ; Sorafenib
  • Indications Renal cell carcinoma
  • Focus Pharmacogenomic; Therapeutic Use
  • Sponsors Amgen

    • Most Recent Events

    • 09 Feb 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov
    • 21 Feb 2014 According to the ClinicalTrials.gov record, planned end date changed from 1 Sep 2013 to 1 Dec 2014.
    • 27 Nov 2012 Planned End Date changed from 1 Nov 2012 to 1 Sep 2013 as reported by ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top